New CLL Drug Data to Be Presented at ASH

Adults with relapsed or refractory CLL who have progressed on BTK inhibitors may gain a new oral option if trials succeed.

Updated on Nov. 5, 2026 in Diseases

Bold flat-color vector editorial illustration of a pale oval tablet beside angular teal and oxblood protein-like forms, evoking an investigational oral leukemia therapy.
Nurix Therapeutics will present new clinical data on its investigational oral BTK degrader bexobrutideg for relapsed or refractory CLL at the ASH meeting in New Orleans on December 13, 2026. AI Illustration. Upload story photo >

Nurix Therapeutics, a clinical-stage biopharmaceutical company based in Brisbane, California, announced that new and updated clinical data on its investigational oral BTK degrader bexobrutideg (NX-5948) will be presented at the 68th ASH Annual Meeting in New Orleans. The data concern patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and will be shown as a poster on December 13, 2026, for readers tracking new treatment options in California and beyond.

Why it matters

Patients with CLL who have already received covalent BTK inhibitors have limited options when their disease returns, so early efficacy data in that group is closely watched by oncologists and patient communities. The presentation at a major hematology meeting is a step toward wider review of the drug, which is being co-developed by Nurix and Roche.

The data come from clinical trial reporting in patients with relapsed or refractory CLL or SLL who had previously received covalent BTK inhibitors. Results will be shown as a poster, while the randomized Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib is still ongoing and its outcomes are not yet reported.

The players

Nurix Therapeutics

A Brisbane, California-based clinical-stage biopharmaceutical company developing targeted protein degraders for cancer and immune-mediated diseases.

Roche

A global pharmaceutical company with major oncology and hematology programs, co-developing bexobrutideg with Nurix.

American Society of Hematology (ASH)

A professional society of blood specialists that hosts the annual meeting where major hematology and blood cancer research is presented.

The details

Bexobrutideg is a BTK degrader, meaning it is designed to reduce the amount of the Bruton's tyrosine kinase protein inside cancer cells rather than only blocking its activity. It is taken orally at 600 mg once daily, the dose selected for Phase 2 testing. Nurix and Roche are developing the drug together, and the poster will be presented in session 642 on chronic lymphocytic leukemia at the meeting.

Timeline

  1. November 5, 2026: ASH released the presentation abstract and Nurix announced the upcoming data.

  2. December 12-15, 2026: The 68th ASH Annual Meeting and Exposition is held in New Orleans, Louisiana.

  3. December 13, 2026: The bexobrutideg poster session runs from 6:00 to 8:00 PM in Hall F.

Health Landscape

BTK inhibitors have become a standard treatment class for CLL, and newer agents like degraders are being developed for patients whose disease progresses after those drugs. Data presented at the ASH meeting is one of the main ways the field tracks whether these next-generation approaches can extend options for patients who have run out of established choices.

If you or a family member has CLL and has been treated with a BTK inhibitor, this research is worth discussing with your oncologist as a possible future option in clinical trials. Clinical trial details for bexobrutideg are available through ClinicalTrials.gov, and any decision about treatment should be made with your care team.

The takeaway

Early data suggest bexobrutideg may help patients with CLL whose disease has progressed after covalent BTK inhibitors, though larger trial results are still pending. Readers living with CLL can ask their oncologist whether clinical trials for newer BTK-targeted therapies are an appropriate option to explore.

What happens next

The full set of bexobrutideg data, including analyses in BTK inhibitor-naïve and treatment-naïve patients, will be presented at the 68th ASH Annual Meeting on December 13, 2026.

Further reading

For more background on how these treatments are developed and tested, explore our Cancer coverage.

More information

Find clinical trial information for bexobrutideg studies on the ClinicalTrials.gov registry.

Source note: This article includes information reported by The Manila times.